Addex Therapeutics (ADXN) Change in Account Payables (2019 - 2026)

Addex Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at -$130.9 billion in Q1 2026.

• Quarterly Change in Account Payables fell 176.76% year-over-year to -$130.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1065.9 billion (up 222.16% YoY) and the FY2025 annual result came in at $471878.5, up 136.22% from the prior year.
• Change in Account Payables improved to -$130.9 billion in Q1 2026 per ADXN's latest filing, from -$185.3 billion in the prior quarter.
• Over five years, Change in Account Payables peaked at $1411.3 billion in Q4 2023 and troughed at -$1224.9 billion in Q3 2024.
• A 5-year average of -$7.8 billion and a median of -$314481.6 in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables tumbled 246610803.76% in 2023, then surged 18946372486.98% in 2024.
• Over 5 years, Change in Account Payables stood at -$821184.3 in 2022, then jumped by 171865410.82% to $1411.3 billion in 2023, then dropped by 14.16% to $1211.5 billion in 2024, then plunged by 115.29% to -$185.3 billion in 2025, then rose by 29.32% to -$130.9 billion in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$130.9 billion, -$185.3 billion, and $170.6 billion for Q1 2026, Q2 2025, and Q1 2025 respectively.